YuiData Reaches 30 Partner Hospitals Across Japan
Yuimedi's real-world data service for pharmaceutical companies has grown to approximately 30 partner hospitals, spanning national university hospitals and regional medical centers across Japan.
Yuimedi's real-world data service, YuiData, has reached a significant milestone: approximately 30 hospitals across Japan are now contributing clinical data to the network. The list includes national university hospitals, municipal institutions, and regional core hospitals, among them Chiba University Hospital, Nagoya University Hospital, Okayama University Hospital, Tokushima University Hospital, and Ryukyu University Hospital.
Building a Clinical Data Network That Matters
YuiData gives pharmaceutical companies structured access to real-world data drawn directly from electronic health records. This is a meaningful distinction in the Japanese healthcare landscape, where claims-based data has historically been the default. EHR data captures far more of the clinical picture: how diseases present in practice, how patients respond to treatment outside of trial conditions, and how outcomes vary across populations and regions.
With 30 institutions now participating, pharmaceutical clients can select specific hospitals and data types tailored to their research or commercial objectives. The result is evidence that is more granular, more current, and more clinically grounded than what legacy data sources have historically offered.
Voices from the Network
Dr. Tetsuo Hirata, Vice President of Ryukyu University Hospital, described the expansion as accelerating the implementation of next-generation medicine, where individual patient data connects meaningfully with Japan's healthcare industry to deliver optimal treatment to each person.
Dr. Yoshifumi Wakita of Tokushima University Hospital noted that participation creates an opportunity not just for nationwide research and development, but for exploring early diagnostic indicators, validating treatment outcomes across regional contexts, and supporting new drug discovery.
Dr. Shunsuke Doi of Chiba University Hospital was direct: the era of hospitals holding data in silos is over. Contributing statistical information is now a form of social contribution that extends a hospital's impact well beyond its own walls.
What Comes Next
This expansion follows Yuimedi's 400M JPY funding round announced in February 2026, backed by DG Daiwa Ventures, Sumitomo Mitsui Trust Bank, HearstLab, and SMBC Venture Capital. The company will use that investment to grow its YuiData business development team, continue expanding the hospital network, and strengthen its ability to serve pharmaceutical clients with richer, more diverse clinical datasets.
Yuimedi's mission remains constant: delivering the right care to the right patients through data. YuiData is one of the clearest expressions of that mission in practice.
About Yuimedi
Yuimedi was founded in November 2020 and is headquartered in Tokyo, Japan, with US operations based in Somerville, Massachusetts. The company builds infrastructure for medical data access spanning data standardization, real-world data services, and AI-powered research tools.
